Suppr超能文献

手术在转移性膀胱癌中的作用:系统评价。

The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.

机构信息

Department of Urology, Medical University of Vienna, Vienna, Austria; Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.

Urology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

出版信息

Eur Urol. 2018 Apr;73(4):543-557. doi: 10.1016/j.eururo.2017.09.030. Epub 2017 Nov 7.

Abstract

CONTEXT

The role of surgery in metastatic bladder cancer (BCa) is unclear.

OBJECTIVE

In this collaborative review article, we reviewed the contemporary literature on the surgical management of metastatic BCa and factors associated with outcomes to support the development of clinical guidelines as well as informed clinical decision-making.

EVIDENCE ACQUISITION

A systematic search of English language literature using PubMed-Medline and Scopus from 1999 to 2016 was performed.

EVIDENCE SYNTHESIS

The beneficial role of consolidation surgery in metastatic BCa is still unproven. In patients with clinically evident lymph node metastasis, data suggest a survival advantage for patients undergoing postchemotherapy radical cystectomy with lymphadenectomy, especially in those with measurable response to chemotherapy (CHT). Intraoperatively identified enlarged pelvic lymph nodes should be removed. Anecdotal reports of resection of pulmonary metastasis as part of multimodal approach suggest possible improved survival in well-selected patients. Cytoreductive radical cystectomy as local treatment has also been explored in patients with metastatic disease, although its benefits remain to be assessed.

CONCLUSIONS

Consolidative extirpative surgery may be considered in patients with clinically evident pelvic or retroperitoneal lymph nodal metastases but only if they have had a response to CHT. Surgery for limited pulmonary metastases may also be considered in very selected cases. Best candidates are those with resectable disease who demonstrate measurable response to CHT with good performance status. In the absence of data from prospective randomized studies, each patient should be evaluated on an individual basis and decisions made together with the patient and multidisciplinary teams.

PATIENT SUMMARY

Surgical resection of metastases is technically feasible and can be safely performed. It may help improve cancer control and eventually survival in very selected patients with limited metastatic burden. In a patient who is motivated to receive chemotherapy and to undergo extirpative surgical intervention, surgery should be discussed with the patient among other consolidation therapies in the setting of multidisciplinary teams.

摘要

背景

手术在转移性膀胱癌(BCa)中的作用尚不清楚。

目的

在这篇合作综述文章中,我们回顾了有关转移性 BCa 手术治疗的当代文献以及与结局相关的因素,以支持临床指南的制定和知情的临床决策。

证据获取

使用 PubMed-Medline 和 Scopus 从 1999 年到 2016 年进行了英语文献的系统搜索。

证据综合

巩固性手术在转移性 BCa 中的有益作用仍未得到证实。在有临床明显淋巴结转移的患者中,数据表明接受化疗后根治性膀胱切除术加淋巴结切除术的患者有生存优势,特别是在对化疗有可测量反应的患者中。应切除术中发现的增大的盆腔淋巴结。作为多模式治疗一部分切除肺转移的偶然报告表明,在精选的患者中可能改善生存。作为局部治疗的细胞减灭性根治性膀胱切除术也已在转移性疾病患者中进行了探索,尽管其益处仍有待评估。

结论

如果患者对 CHT 有反应,临床上有明显的骨盆或腹膜后淋巴结转移,可考虑进行巩固性切除术。在非常特定的情况下,也可考虑对有限的肺转移灶进行手术。最佳候选者是那些有可切除疾病的患者,这些患者对 CHT 有可测量的反应且表现出良好的体能状态。在缺乏前瞻性随机研究数据的情况下,应根据每位患者的具体情况进行评估,并与患者和多学科团队一起做出决策。

患者总结

转移性病灶的外科切除在技术上是可行的,并且可以安全进行。在极少数转移负担有限的患者中,它可能有助于改善癌症控制并最终提高生存率。对于有动机接受化疗并接受根治性手术干预的患者,应在多学科团队的背景下与患者讨论手术作为其他巩固性治疗之一。

相似文献

1
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review.
Eur Urol. 2018 Apr;73(4):543-557. doi: 10.1016/j.eururo.2017.09.030. Epub 2017 Nov 7.
2
The role of metastatic burden in cytoreductive/consolidative radical cystectomy.
World J Urol. 2019 Dec;37(12):2691-2698. doi: 10.1007/s00345-019-02693-y. Epub 2019 Mar 12.
3
Role of Radical Cystectomy in Non-Organ Confined Bladder Cancer: A Systematic Review.
Bladder Cancer. 2018 Jan 20;4(1):31-40. doi: 10.3233/BLC-170130.
4
Lymphadenectomy for bladder cancer at the time of radical cystectomy.
Eur Urol. 2013 Aug;64(2):266-76. doi: 10.1016/j.eururo.2013.04.036. Epub 2013 Apr 29.
6
Lymphadenectomy in bladder cancer: how high is "high enough"?
Urol Oncol. 2006 Jul-Aug;24(4):349-55. doi: 10.1016/j.urolonc.2005.07.013.
7
The impact of lymphadenectomy and lymph node metastasis on the outcomes of radical cystectomy for bladder cancer.
Eur Urol. 2009 Apr;55(4):826-35. doi: 10.1016/j.eururo.2009.01.004. Epub 2009 Jan 13.
8
EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.
Eur Urol. 2014 Apr;65(4):778-92. doi: 10.1016/j.eururo.2013.11.046. Epub 2013 Dec 12.

引用本文的文献

1
Rare Breast Metastasis From Urothelial Carcinoma: A Case Report and Literature Review.
Cureus. 2025 Jun 11;17(6):e85779. doi: 10.7759/cureus.85779. eCollection 2025 Jun.
2
Salvage Surgery Following Remarkable Tumor Shrinkage With Enfortumab Vedotin in Advanced Urothelial Carcinoma.
IJU Case Rep. 2025 Apr 8;8(3):257-260. doi: 10.1002/iju5.70019. eCollection 2025 May.
3
LINC00461 promotes bladder cancer cells EMT through miR-518b/HNRNPUL1 axis.
Discov Oncol. 2024 Sep 10;15(1):419. doi: 10.1007/s12672-024-01294-5.
4
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives.
Signal Transduct Target Ther. 2024 Aug 2;9(1):192. doi: 10.1038/s41392-024-01885-2.
8
The evolving treatment landscape of metastatic urothelial cancer.
Nat Rev Urol. 2024 Oct;21(10):580-592. doi: 10.1038/s41585-024-00872-0. Epub 2024 May 3.
9
Low Cubilin/Myeloperoxidase ratio as a promising biomarker for prognosis of high-grade T1 bladder cancer.
Int Urol Nephrol. 2024 Aug;56(8):2577-2587. doi: 10.1007/s11255-024-03971-4. Epub 2024 Mar 26.
10
Surgery for pulmonary lesions in patients with a history of urinary tract transitional cell carcinoma.
J Cardiothorac Surg. 2024 Mar 12;19(1):117. doi: 10.1186/s13019-024-02607-z.

本文引用的文献

2
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.
N Engl J Med. 2017 Mar 16;376(11):1015-1026. doi: 10.1056/NEJMoa1613683. Epub 2017 Feb 17.
3
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial.
Lancet Oncol. 2017 Mar;18(3):312-322. doi: 10.1016/S1470-2045(17)30065-7. Epub 2017 Jan 26.
6
Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?
J Clin Oncol. 2016 Oct 10;34(29):3495-3498. doi: 10.1200/JCO.2016.68.3714.
7
The Role of Cytoreductive Nephrectomy: European Association of Urology Recommendations in 2016.
Eur Urol. 2016 Dec;70(6):901-905. doi: 10.1016/j.eururo.2016.07.005. Epub 2016 Jul 18.
8
Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer.
Eur Urol. 2017 Mar;71(3):462-475. doi: 10.1016/j.eururo.2016.06.020. Epub 2016 Jun 30.
10
Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.
J Clin Oncol. 2016 Aug 1;34(22):2627-35. doi: 10.1200/JCO.2016.67.5033. Epub 2016 Jun 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验